Newsletter Subject

Should You Buy Canopy or Acreage?

From

cannabisprofitsdaily.com

Email Address

cannabisprofitsdaily@e.cannabisprofitsdaily.com

Sent On

Sat, Apr 27, 2019 11:05 AM

Email Preheader Text

You are receiving this as part of your free subscription to Cannabis Profits Daily. To remove your e

You are receiving this as part of your free subscription to Cannabis Profits Daily. To remove your email from this list, [unsubscribe here](. [Cannabis Profits Daily] Saturday, April 27, 2019 Q&A: What Happens to My Stocks in an Acquisition? By Greg Miller We had another exciting week here at the National Institute for Cannabis Investors. After the announcement of a [massive deal]( that will marry the largest Canadian cannabis company with one of the largest U.S. multi-state cannabis operators, we determined that the industry has entered what we refer to as "[Phase 2](." Cannabis IPO Expert Danny Brody wrote in to give his thoughts on this transition. If you haven't had a chance to see his report yet, I encourage you to see why he thinks [this new era will be massively profitable](. With all this news about mergers and acquisitions, I wanted to take a moment to address some questions our members have about the impact of this new phase. Darryl S. comments: "I'm not sure I understand what happens with the stock I own in a company when it gets acquired by another company. Do my shares roll into the company that just bought the smaller company? Or do they still trade under the same ticker?" It depends on the deal, Darryl. Only rarely does the acquired company get to trade under its own ticker, but it happens, as we'll see. Most often, when the company you own gets acquired, you get cash, shares in the acquiring company, or both. Sometimes you'll get something extra, too. For example, when iAnthus Holdings (CSE: [IAN](, OTC: [ITHUF]() bought MPX Bioceuticals, MPX shareholders got shares of iAnthus but they also got a "mini-company" of assets that MPX did not sell. So people who held MPX got two companies, one with the symbol IAN and one with the symbol MPXI. The just-announced deal between Canopy Growth (NYSE: [CGC]() and Acreage Holdings (CSE: [ACRG](, OTC: [ACRGF]() is even more complex. Acreage shareholders will get some cash as soon as the deal is approved, and they will eventually get Canopy shares, but they'll only receive the Canopy shares after cannabis is legal on a federal level in the United States. That means shareholders will retain their Acreage shares for at least a few more months, but those shares will trade more closely with the fortunes of Canopy than with the fortunes of the company they actually own! So what's the right strategy? To answer that question, we can look at what Dave wrote in. Dave N. says: "Whenever Canopy dips, I try to buy more. Just wondering if I should continue that or buy Acreage shares instead? Thanks for what you do!!!" That's an outstanding question, Dave. For our other readers, you know that Canopy has agreed to acquire Acreage Holdings at a fixed share ratio, meaning Acreage stock should trade in tandem with Canopy stock. And Acreage is currently trading at a discount to Canopy stock, which means that if you buy Acreage stock you should get both the movement of Canopy stock and the narrowing of that discount as the completion of the merger nears. The answer, Dave, depends on your risk tolerance. I think the deal will close sooner than most people are projecting, but there is still some risk in holding Acreage stock. For example, what if something goes wrong at Acreage which allows Canopy to cancel the deal? If you think the risk of that is low, go ahead and start accumulating Acreage Holdings stock - it's like buying Canopy at a big discount! For our members, though, I'm going to stick with the lower-risk approach of continuing to recommend Canopy directly, in part because it's a lot simpler for many of our newer investors. Finally, one of our readers came across a report that deserves some attention. Alma writes in to say: "E-Trade had a report saying that Marijuana investors are as oblivious to the litigation risks as the smokers are to the health risks from smoking. I am just interested in your response since yesterday they were up and today since that came out they are dropping fast." Thank you for bringing this story up, Alma. I saw that same report, and I'm happy to have the opportunity to write about it. The risk of litigation exists in any industry, and it's true that there is a lot not yet known about the long-term effects of cannabis use. We do know that some of the nastiest parts of tobacco, like "tar," do not exist in the cannabis plant. Ultimately, I think the risk of serious litigation on health-related matters is vanishingly small in the next decade or so. For one thing, an increasing number of people are consuming cannabis by methods other than smoking, like vaping and edibles. For another, the mental health risks the author of that report discusses are not well established among people who didn't already have a mental health disorder. And with what we're learning these days, it seems increasingly likely that cannabis could well turn out to be a treatment or cure for some of the very maladies that author describes as risks. It is true that the cannabis market has been weak since that article, but I think that's a coincidence. If you've been investing in this sector for a while, you'll notice that the market has occasional weak patches with massive upswings between them. I think we're just in one of those soft spots, which means it's a good time to accumulate cannabis stocks if you haven't already. [Make sure you know how](. Greg Miller Executive Director, National Institute for Cannabis Investors P.S. We have a brand-new video from Cannabis Options Expert Tom Gentile. In [this video](, Tom explains his three-step approach to trading and his rules for success. Be sure to [take a look](! Are You Ready to Take Your Interest in Cannabis to the Next Level? If you haven't added our [one-of-a-kind stock database]( to your investing toolkit, you could be missing out on the biggest, fastest cannabis gains this lucrative industry has to offer. It gives concise, detailed information about each firm's financials, executive team, operations, you name it. [We cover everything you need to know so you can decide if the company is right for you](. Fact is, this kind of in-depth analysis isn't available anywhere else. Hedge funds and venture capitalists would happily pay $30,000 or more for this kind of research. And if you [click here](, we can show you how to access it for yourself for a fraction of the cost. [The Potential for Marijuana Millions Made Easy: How You Can Pinpoint the BEST Opportunities in Cannabis]( One of the only things that sets millionaires apart from the crowd is the right knowledge - and nowhere on the planet will you find a more detailed and comprehensive database of cannabis stocks than [right here](. This kind of information is not available to everyone... and it could be the only difference between you and your next million-dollar opportunity. To see how you can get immediate access, [click here](. [America's Green Gold Rush Is Just Getting Starting - Claim Your Stake Now]( At this very moment, big investment firms and members of the Fortune 500 are building enormous war chests. They're preparing to push billions upon billions of dollars into the cannabis market - and they could strike at any moment. So [right here]( - right now - you have a once-in-a-lifetime opportunity to beat them to the punch and stake your claim. [Click here to learn how](. [Critical: These IPOs Could Put Billions of New Wealth on the Table]( [These tiny cannabis companies]( are about to make their move into the public spotlight with some of the most groundbreaking innovations we've ever seen. If you act now, you could take home a piece of the projected $12 billion in new wealth. But game changers like these won't remain under the radar for long. To see how to make what could end up being the best investment of your life, [click here](. --------------------------------------------------------------- You are receiving this e-mail at {EMAIL}, as a part of your subscription. Remove your email from this list: [Unsubscribe]( © 2019 The National Institute for Cannabis Investors All Rights Reserved The National Institute for Cannabis Investors | 1125 N Charles Street | Baltimore, MD 21201 Toll Free: 866.260.0361; International: 410.777.8270 [Contact Customer Service](mailto:support@nicinvestors.com?subject=Cannabis%20Profits%20Daily%20Question) Website: []( Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This information may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The National Institute for Cannabis Investors, 1125 N Charles Street, Baltimore, MD 21201. [Privacy Policy]( | [Terms & Conditions](

Marketing emails from cannabisprofitsdaily.com

View More
Sent On

27/07/2020

Sent On

19/07/2020

Sent On

12/07/2020

Sent On

05/07/2020

Sent On

05/07/2020

Sent On

28/06/2020

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.